PEMBROLIZUMAB
UC-BCG-2401
Phase 3 small_molecule active
Quick answer
PEMBROLIZUMAB for Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab. is a Phase 3 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active